A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Antiretroviral therapy suppresses HIV-1 replication but cannot eliminate the latent viral reservoir persisting in memory CD4 T cells. Existing latency reversal candidates have yet to achieve robust viral reactivation at tolerable doses. We engineered T4IL15Δ, a bispecific biologic that selectively delivers IL-15 signaling to memory CD4 T cells, with minimal off-target stimulation. T4IL15Δ reactivated latent virus in 94% (48/51) of clinical samples ex vivo, 75% (15/20) of administrations in HIV-1-infected and ART-suppressed humanized mice, and 100% (6/6) of SIV-infected and ART-suppressed rhesus macaques at doses well tolerated. We also found that off-target stimulation of non-CD4 cells hindered HIV-1 reactivation ex vivo. T4IL15Δ provides a robust reactivation platform that could complement other reservoir-elimination strategies toward an HIV-1 cure.

Article activity feed

  1. A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency https://www.biorxiv.org/content/10.64898/2026.10.06.757104v1

  2. A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency https://www.biorxiv.org/content/10.64898/2026.10.06.757104v1